Manipulation and Exploitation of the Tumour Environment for Therapeutic Benefit

References

• Adams G.E., Bremner J.C.M., Edwards H.S., Fielden E.M., Naylor M., Stratford I.J., Wood P. Bioreductive drugs: dual function agents and related compounds. Radiation Research: A 20th Century Perspective, W.C. Dewey, M. Edington, R.J.M. Fry, E.J. Hall, G.F. Whitmore. Academic, San Diego 1992a; II: 802–806, In
   Google Scholar
• Adams G.E., Stratford I.J., Edwards H.S., Bremner J.C.M., Cole S. Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR4233 and the mitomycin C analogue E09. International Journal of Radiation Oncology, Biology and Physics 1992b; 22: 717–720
   PubMed Web of Science ®Google Scholar
• Bicknell R., Harris A.L. Anti-cancer strategies involving the vasculature. Vascular targeting and the inhibition of angiogenesis. Seminars in Cancer Biology 1992; 3: 399–407
   PubMedGoogle Scholar
• Braddock P.S., Hu D.E., Fan T.-P.D., Stratford I.J., Harris A.L., Bicknell R. A structureactivity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions. British Journal of Cancer 1994, in press
   PubMedGoogle Scholar
• Braunschweiger P.G., Jones S., Johnson C., Furmanski P. Interleukin-1α induced tumour vascular pathophysiologics can be exploited with bioreductive alkylating agents. International Journal of Radiation Biology 1991; 60: 369–373
   PubMed Web of Science ®Google Scholar
• Bremner J.C.M., Adams G.E., Pearson J.K., Stratford I.J., Bedwell J., Bown S.G., Macrobert A.J., Phillips D. Increasing the effect of photodynamic therapy on the RIF-1 tumour using the bioreductive drugs RSU1069 and RB6145. British Journal of Cancer 1992; 66: 1070–1076
   PubMed Web of Science ®Google Scholar
• Bremner J.C.M., Breadley J.K., Adams G.E., Naylor M.A., Sansom J.M., Stratford I.J. Comparing the anti-tumour effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT). International Journal of Radiation Oncology, Biology and Physics 1993, in press
   Google Scholar
• Bremner J.C.M., Stratford I.J., Bowler J., Adams G.E. Bioreductive drugs and the selective induction of tumour hypoxia. British Journal of Cancer 1990; 61: 717–721
   PubMed Web of Science ®Google Scholar
• Brown J.M. Targeting bioreductive drugs to tumours: is it necessary to manipulate blood flow?. International Journal of Radiation Biology 1991; 60: 231–236
   PubMed Web of Science ®Google Scholar
• Brown J.M., Lemmon M.J. Potentiation by the hypoxic cytotoxin SR4233 of cell killing produced by fractionated irradiation of mouse tumours. Cancer Research 1990; 50: 7745–7749
   PubMed Web of Science ®Google Scholar
• Brown J.M., Lemmon J.J. SR4233: a tumour specific radiosensitizer active in fractionated regimes. Radiotherapy and Oncology 1991a; 20: 151–156
   PubMed Web of Science ®Google Scholar
• Brown J.M., Lemmon J.J. Tumour hypoxia can be exploited to preferentially sensitize tumours to fractionated radiation. International Journal of Radiation Oncology, Biology and Physics 1991b; 20: 457–461
   PubMed Web of Science ®Google Scholar
• Bush R.S., Jenkin R.D.T., Allt W.E.C., Beale F.A., Bean H.A., Dembo A.J., Pringle J.F. Definitive evidence for hypoxic cells influencing cure in cancer therapy. British Journal of Cancer 1978; 37: 255–258
   Google Scholar
• Chaplin D.J. Post-irradiation modification of tumor blood flow: a method to increase the effectiveness of chemical radiosensitizers. Radiation Research 1988; 115: 292–302
   PubMed Web of Science ®Google Scholar
• Chapman J.D. Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies. Radiotherapy and Oncology 1991; S20: 13–19
   Google Scholar
• Coleman C.N., Carlson R.W., Halsey J., Kohler M., Gribble B.I., Jacobs C. Enhancement of the clinical activity of melphalen by the hypoxic cell sensitizer misonidazole. Cancer Research 1988; 48: 3528–3532
   PubMedGoogle Scholar
• Cresteil T., Jaiswal A.K. High levels of expression of the NAD(P)H:(quinone acceptor) oxidoreductase (NQ01) gene in tumour cells compared to normal cells of the same origin. Biochemical Pharmacology 1991; 42: 1021–1027
   PubMed Web of Science ®Google Scholar
• Denekamp J., Hobson B. Endothelial cell proliferation in experimental tumours. British Journal of Cancer 1982; 46: 711–720
   PubMed Web of Science ®Google Scholar
• Dische S. Radiotherapy and anaemia: the clinical experience. Radiotherapy and Oncology 1991; 20: 135–140, (Suppl.)
   Google Scholar
• Dorie M.J., Brown J.M. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Research 1993; 53: 4633–4636
   PubMed Web of Science ®Google Scholar
• Edwards H.S., Bremner J.C.M., Stratford I.J. Induction of tumour hypoxia by FAA and TNF: interaction with bioreductive drugs. International Journal of Radiation Biology 1991; 60: 373–377
   PubMed Web of Science ®Google Scholar
• Gatenby R.A., Kessler H.B., Rosenblum J.S., Coia L.R., Moldofsky P.J., Hartz W.H., Broder G.J. Oxygen distribution in squamous cell carcinoma metastases and its relationship to the outcome of radiation therapy. International Journal of Radiation Oncology, Biology and Physics 1988; 14: 831–838
   PubMed Web of Science ®Google Scholar
• Haffty B.G., Son Y.H., Sasaki C.T., Papac R., Fischer D., Rockwell S., Sartorelli A., Fischer J.J. Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomised clinical trials. International Journal of Radiation Oncology, Biology and Physics 1993; 27: 241–250
   PubMed Web of Science ®Google Scholar
• Hasan N.M., Cundall R.B., Adams G.E. Effects of hypoxia and reoxygenation on the conversion of xanthine dehydrogenase to oxidase in Chinese hamster V79 cells. Free Radical Biology and Medicine 1991; 11: 179–185
   PubMedGoogle Scholar
• Höckel M., Knoop C., Schlenger K., Vorndran B., Baussman E., Mitze M., Knapstein P.G., Vaupel P. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiotherapy and Oncology 1993; 26: 45–50
   PubMed Web of Science ®Google Scholar
• Höckel M., Schlenger K., Knoop C., Vaupel P. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Research 1991; 51: 6098–6102
   PubMed Web of Science ®Google Scholar
• Holden S.A., Teicher G.A., Ara G., Herman T.S., Coleman C.N. Enhancement of alkylating agent activity by SR4233 in the FSaIIC murine fibrosarcoma. Journal of the National Cancer Institute 1992; 84: 187–193
   PubMed Web of Science ®Google Scholar
• Jahde E., Glusenkamp K.-H., Klunder I., Husler D.F., Tietze L.-F., Rajewsky M.F. Hydrogen ion-mediated enhancement of cytotoxicity of bischloroethylating drugs in rat mammary carcinoma cells in vitro. Cancer Research 1989; 49: 2965–2972
   PubMed Web of Science ®Google Scholar
• Kennedy K.A., Rockwell S., Sartorelli A.C. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumour cells. Cancer Research 1980; 40: 2356–2360
   PubMed Web of Science ®Google Scholar
• Lloyd D.V., Duling D.R., Rumyantseva G.A., Mason R.P., Bridson P.K. Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical. Molecular Pharmacology 1991; 40: 440–445
   PubMed Web of Science ®Google Scholar
• Malkinson A.M., Siegel D., Forrest G.L., Gazdar A.F., Oie H.K., Chan D.C., Bunn P.A., Mabry M., Dykes D.J., Harrison S.D., Ross D. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumour xenografts to mitomycin C. Cancer Research 1992; 52: 4752–4757
   PubMed Web of Science ®Google Scholar
• Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacological Reviews 1991; 43: 109–141
   PubMed Web of Science ®Google Scholar
• Murphy B.J., Laderoute K.R., Short S.M., Sutherland R.M. The identification of heme oxygenase as a major hypoxic stress protein in Chinese hamster ovary cells. British Journal of Cancer 1991; 64: 69–73
   PubMed Web of Science ®Google Scholar
• Naylor M.A., Stephens M.A., Nolan J., Sutton B., Tocher J.H., Fielden E.M., Adams G.E., Stratford I.J. Heterocyclic mono-N-oxides with potential applications as bioreductive anti-tumour drugs: Part 1: 8-alkylamino-substituted phenylimidazol [1,2-a]quinoxalines. Anti-Cancer Drug Design 1994, in press
   Google Scholar
• O'Dwyer P.J., Yao K.S., Godwin A.K., Clayton M. Effects of hypoxia upon detoxicating enzyme activity and expression in HT29 colon adenocarcinoma cells. Proceedings of the American Association for Cancer Research 1993; 68: 34–34, (Abs).
   Google Scholar
• Okunieff P., Hoeckel M., Dunphy E.P., Schlenger K., Knoop C., Vaupel P. Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. International Journal of Radiation Oncology, Biology and Physics 1993; 26: 631–636
   PubMed Web of Science ®Google Scholar
• Overgaard J. Importance of tumour hypoxia in radiotherapy: a meta-analysis of controlled clinical trials. Radiotherapy and Oncology 1992; 24: S64–S64
   PubMed Web of Science ®Google Scholar
• Pesenti E., Sola F., Mongelli N., Grandi M., Spreafico F. Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. British Journal of Cancer 1992; 66: 367–372
   PubMed Web of Science ®Google Scholar
• Riley R.J., Workman P. Enzymology of the reduction of the potent benzortriazine di-N-oxide hypoxic cell cytotoxin SR4233 (WIN 59075) by NAD(P)H:(quinone acceptor) oxide-reductase (EC 1.66.99.2) purified from Walker 256 rat tumour cells. Biochemical Pharmacology 1992; 43: 167–174
   PubMedGoogle Scholar
• Robertson N., Haigh A., Adams G.E., Stratford I.J. Factors affecting sensitivity to E09 in rodent and human tumour cells in vivo: DT:diaphorase activity and hypoxia. European Journal of Cancer 1994, in press
   Google Scholar
• Robertson N., Stratford I.J., Houlbrook S., Carmichael J., Adams G.E. The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase?. Biochemical Pharmacology 1992; 44: 409–412
   PubMed Web of Science ®Google Scholar
• Rotin D., Steele-Norwood D., Grinstein S., Tannock O. Requirement of the Na+/H+ exchanger for tumour growth. Cancer Research 1989; 49: 205–211
   PubMedGoogle Scholar
• Rowell N.P., Flower M.A., McCready V.R., Cronin B., Horwich A. The effects of single dose oral hydralazine on blood flow through human lung tumours. Radiotherapy and Oncology 1990; 18: 283–292
   PubMed Web of Science ®Google Scholar
• Sagar S.M., Klassen G.A., Barclay K.D., Aldrich J.E. Tumour blood flow: measurement and manipulation for therapeutic gain. Cancer Treatment Reviews 1993; 19: 299–349
   PubMedGoogle Scholar
• Sartorelli A.C. The role of mitomycin antibiotics in the chemotherapy of solid tumours. Biochemical Pharmacology 1986; 35: 67–69
   PubMedGoogle Scholar
• Schlager J.J., Powis G. Cytosolic NAD(P)H:(quinone acceptor) oxidoreductase in human normal and tumour tissue. Effects of cigarette smoking and alcohol. International Journal of Cancer 1990; 45: 403–409
   PubMed Web of Science ®Google Scholar
• Sebolt-Leopold J.S., Elliott W.L., Showalter H.D., Leopold W.R. Rationale for selection of PD144872, the R isomer of RB6145, for clinical development as a radiosensitizer. Proceedings of the American Association for Cancer Research 1993; 34: 362–362, (Abs).
   Google Scholar
• Siemann D.W. Modification of chemotherapy by nitroimidazoles. International Journal of Radiation Oncology, Biology and Physics 1984; 10: 1585–1594
   PubMed Web of Science ®Google Scholar
• Siemann D.W., Chapman M., Beikirch A. Effects of oxygenation and pH on tumour cell response to alkylating chemotherapy. International Journal of Radiation Oncology, Biology and Physics 1991; 20: 287–290
   PubMed Web of Science ®Google Scholar
• Stratford I.J., Adams G.E., Godden J., Howells N. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU1069 in vivo. International Journal of Radiation Biology 1989; 55: 411–422
   PubMed Web of Science ®Google Scholar
• Stratford I.J., Godden J., Howells N., Embling P., Adams G.E. Manipulation of tumour oxygenation by hydralazine increases the potency of bioreductive radiosensitizers and enhances the effect of melphalan in experimental tumours. Radiation Research, E.M. Fielden, J.F. Fowler, J.H. Hendry, D. Scott. Taylor & Francis, London 1987; 2: 737–742, In
   Google Scholar
• Sun J., Brown J.M. The bioreductive drug SR4233 enhances the anti-tumour effect of flavone-acetic acid. Cancer Research 1989; 49: 5664–5670
   PubMedGoogle Scholar
• Tannock I.F., Rotin D. Acid pH in tumours and its potential for therapeutic exploitation. Cancer Research 1989; 49: 4373–4373
   PubMed Web of Science ®Google Scholar
• Teicher B.A., Sotomayor E.A., Huang Z.D. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Research 1992; 52: 6702–6704
   PubMed Web of Science ®Google Scholar
• Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment for human tumors: a review. Cancer Research 1989; 49: 6449–6465
   PubMed Web of Science ®Google Scholar
• Vaupel P., Schlenger K., Knoop C., Höckel M. Oxygenation of human tumours: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Research 1991; 51: 3316–3322
   PubMed Web of Science ®Google Scholar
• Walton M.I., Bibby M.C., Double J.A., Plumb J.A., Workman P. DT-diaphorase activity correlates with sensitivity to the indoloquinone E09 in mouse and mouse colon carcinomas. European Journal of Cancer 1992; 28A: 1597–1600
   PubMed Web of Science ®Google Scholar
• Walton M.I., Workman P. Nitroimidazole bioreductive metabolism. Quantitation and characterization of mouse tissue benzonidazole nitroreductases in vivo and in vitro. Biochemical Pharmacology 1987; 36: 887–896
   PubMedGoogle Scholar
• Walton M.I., Workman P. Enzymology of the reductive bioactivation of SR4233: a novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochemical Pharmacology 1990; 37: 1735–1742
   Google Scholar
• Weissberg J.B., Son Y.H., Papac R.J., Sasaki C., Fischer D.B., Lawrence R., Rockwell S., Sartorelli A.C., Fischer J.J. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. International Journal of Radiation Oncology, Biology and Physics 1989; 17: 3–9
   PubMed Web of Science ®Google Scholar
• Wood P.J., Stratford I.J., Adams G.E., Szabo C., Thiemermann C., Vane J.R. Modification of energy metabolism and radiation response of a murine tumour by changes in nitric oxide availability. Biochemical and Biophysical Research Communications 1993; 192: 505–510
   PubMed Web of Science ®Google Scholar
• Workman P. Bioreductive mechanisms. International Journal of Radiation Oncology, Biology and Physics 1992; 22: 631–637
   PubMed Web of Science ®Google Scholar
• Workman P., Stratford I.J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer and Metastasis Reviews 1993; 12: 73–82
   PubMed Web of Science ®Google Scholar
• Workman P., Walton M.I. Enzyme-directed bioreductive drug development. Selective Activation of Drugs by Redox Processes, G.E. Adams, A. Brecci, P. Wardman, E.M. Fielden. Plenum, New York 1990; 173–191, In
   Google Scholar